1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

Executive Decisions Roundup

 
• By Malcolm Spicer

Another Coca-Cola exec pops up at NBTY; Hussain helms Glaxo pharma globally; China TCM office veteran returns; T-Bird tabs Huang as COO; and Lee named Calif. DTSC director.

[NBTY Inc.] adds another former Coca-Cola Co. executive to its management as Brian Wynne becomes Americas markets head, working with President and CEO Steve Cahillane, also a Coca-Cola veteran. The vitamin and nutritional supplement manufacturer, marketer and retailer said Dec. 8 Wynne will start in January as president of NBTY Americas and CEO of its U.S. subsidiary, United States Nutrition Inc., with general management responsibility and profit and loss accountability for the Ronkonkoma, N.Y.-based firm’s Wholesale Brands in North and South America. Wynne is a 25-year consumer packaged goods industry veteran who most recently served as Coca-Cola’s senior VP Strategy, Franchise Relations & Transformation for North America. Cahillane left his post as president of Coca-Cola’s Americas division in December 2013 and in September took the helm of Carlyle Group-owned NBTY Also see "Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane" - Pink Sheet, 20 August, 2014..

Abbas Hussain, GlaxoSmithKline PLC‘s head of international pharmaceutical business, takes a new role as Global Pharmaceuticals head, in charge...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Expedited Reviews For China-Originated Drugs Shift Back Home

 
• By Xu Hu

The proportion of China-originated drugs granted expedited reviews in China doubled in the first half of this year, Pharmaprojects data show, surpassing those receiving similar treatment in the US and likely driven by multiple factors.

Beijing City Releases AI Action Plan Including Drug Regulation

 
• By Xu Hu

Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By Xu Hu

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 
• By Sarah Karlin-Smith

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

More from Asia

Australia Targets Clinical Trial Reform, AI Use And Drug Shortages In 12-Month Plan

 
• By Eliza Slawther

Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.

Leqembi Facing 15% Price Cut In Japan

 
• By Lisa Takagi

Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.

Beijing City Releases AI Action Plan Including Drug Regulation

 
• By Xu Hu

Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.